Tumor immunology and immunotherapy for endometrial cancer.

IF 4.1 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert opinion on investigational drugs Pub Date : 2025-01-01 Epub Date: 2025-02-11 DOI:10.1080/13543784.2025.2463091

Kosuke Murakami, Shiki Takamura, Kazuhiro Kakimi, Noriomi Matsumura

{"title":"Tumor immunology and immunotherapy for endometrial cancer.","authors":"Kosuke Murakami, Shiki Takamura, Kazuhiro Kakimi, Noriomi Matsumura","doi":"10.1080/13543784.2025.2463091","DOIUrl":null,"url":null,"abstract":"Introduction: Recent clinical trials show the efficacy of immune checkpoint inhibitors (ICIs) or a combination of ICI and poly (ADP-ribose) polymerase (PARP) inhibitors for advanced or recurrent endometrial cancer. However, the basis for such treatment effects remains unclear, hindering the advancement of personalized therapy.Areas covered: This review includes a detailed interpretation of subgroup analysis data from phase III clinical trials for endometrial cancer evaluating the efficacy of chemotherapy plus ICIs (NRG-GY018, RUBY, AtTEnd, KEYNOTE-B21) or chemotherapy plus ICI with/without olaparib (DUO-E). We focused on the relationship between obesity, the effect of PARP inhibitors, and tumor immunity in endometrial cancer, searched for relevant literature published from 2000 to 2024 in PubMed, and conducted a narrative review.Expert opinion: Chemotherapy plus ICI is appropriate for dMMR. Chemotherapy plus ICI and PARP inhibitor may be appropriate for TP53abn type or serous carcinoma because PARP inhibitor enhances the efficacy of ICI by activating the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway. Obese patients may benefit more from ICIs, and this appears to cause the variation in efficacy between regions/countries. Administration for measurable disease appears important to increase the effect of ICIs. Diet and exercise may also be important factors.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"37-48"},"PeriodicalIF":4.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on investigational drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543784.2025.2463091","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Recent clinical trials show the efficacy of immune checkpoint inhibitors (ICIs) or a combination of ICI and poly (ADP-ribose) polymerase (PARP) inhibitors for advanced or recurrent endometrial cancer. However, the basis for such treatment effects remains unclear, hindering the advancement of personalized therapy.

Areas covered: This review includes a detailed interpretation of subgroup analysis data from phase III clinical trials for endometrial cancer evaluating the efficacy of chemotherapy plus ICIs (NRG-GY018, RUBY, AtTEnd, KEYNOTE-B21) or chemotherapy plus ICI with/without olaparib (DUO-E). We focused on the relationship between obesity, the effect of PARP inhibitors, and tumor immunity in endometrial cancer, searched for relevant literature published from 2000 to 2024 in PubMed, and conducted a narrative review.

Expert opinion: Chemotherapy plus ICI is appropriate for dMMR. Chemotherapy plus ICI and PARP inhibitor may be appropriate for TP53abn type or serous carcinoma because PARP inhibitor enhances the efficacy of ICI by activating the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway. Obese patients may benefit more from ICIs, and this appears to cause the variation in efficacy between regions/countries. Administration for measurable disease appears important to increase the effect of ICIs. Diet and exercise may also be important factors.

查看原文本刊更多论文

子宫内膜癌的肿瘤免疫学和免疫治疗。

最近的临床试验显示免疫检查点抑制剂（ICI）或ICI与聚（adp -核糖）聚合酶（PARP）抑制剂联合治疗晚期或复发性子宫内膜癌的疗效。然而，这种治疗效果的基础仍不清楚，阻碍了个性化治疗的发展。涵盖领域：本综述包括对子宫内膜癌III期临床试验亚组分析数据的详细解释，评估化疗加ICI （NRG-GY018， RUBY, AtTEnd, KEYNOTE-B21）或化疗加ICI加/不加奥拉帕尼（DUO-E）的疗效。我们针对子宫内膜癌中肥胖、PARP抑制剂作用与肿瘤免疫之间的关系，检索PubMed 2000 - 2024年发表的相关文献，并进行叙述性综述。专家意见：化疗加ICI适合dMMR。化疗加ICI和PARP抑制剂可能适合于TP53abn型或浆液性癌，因为PARP抑制剂通过激活环鸟苷单磷酸腺苷单磷酸合成酶(cGAS)-干扰素基因刺激因子（STING）途径增强ICI的疗效。肥胖患者可能从胰岛素注射中获益更多，这似乎导致了不同地区/国家之间疗效的差异。对可测量疾病的管理对于增加ICIs的效果似乎很重要。饮食和运动也可能是重要因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert opinion on investigational drugs 医学-药学

CiteScore

10.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.